{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:53:31Z","timestamp":1791014011941,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Aberrant p53 expression may have prognostic significance in colorectal cancer; however, its role in patients with colorectal liver metastases (CRLM) who receive neoadjuvant chemotherapy but do not achieve pathological complete response (pCR) remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>We evaluated whether aberrant p53 expression assessed by immunohistochemistry (IHC) predicts recurrence\u2010free survival (RFS) in patients with CRLM receiving neoadjuvant FOLFOXIRI followed by resection without achieving pCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>\n                      A prospective cohort study was conducted on 39 patients with CRLM who met the inclusion criteria. All patients received neoadjuvant chemotherapy with the FOLFOXIRI regimen. Following surgical resection of both primary colorectal tumors and liver metastases, none of the patients achieved pCR. Immunohistochemistry was performed to assess p53 expression in resected liver metastasis specimens using a pattern\u2010based interpretation model. RFS was analyzed using univariate and multivariate Cox proportional hazards models. Aberrant p53 expression was observed in 20 patients (51.3%). In univariate analysis, aberrant p53 expression (HR\u2009=\u20092.20; 95% CI: 1.02\u20134.71;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.043), total tumor size &gt;\u20096\u2009cm (HR\u2009=\u20095.62; 95% CI: 2.31\u201313.68;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), number of liver metastases &gt;\u20094 (HR\u2009=\u20094.41; 95% CI: 1.59\u201312.26;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), and positive surgical margin (HR\u2009=\u20092.62; 95% CI: 1.16\u20135.91;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) were significantly associated with recurrence. In multivariate analysis, aberrant p53 expression (HR\u2009=\u20093.78; 95% CI: 1.56\u20139.15;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) and total tumor size &gt;\u20096\u2009cm (HR\u2009=\u20095.23; 95% CI: 1.56\u201317.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007) remained independent prognostic factors for shorter RFS.cnr270701_RedLinePDF.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Aberrant p53 expression, as assessed by immunohistochemistry on post\u2010neoadjuvant chemotherapy specimens, is an independent prognostic factor for early recurrence in patients with CRLM who did not achieve pCR. Together with total tumor size, aberrant p53 expression may serve as a useful marker for risk stratification and personalized postoperative treatment strategies in this high\u2010risk patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70701","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:24:45Z","timestamp":1791012285000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pattern\u2010Based P53 Immunohistochemistry Predicts Recurrence in Colorectal Liver Metastases Without Complete Pathologic Response After Neoadjuvant Chemotherapy"],"prefix":"10.1002","volume":"9","author":[{"given":"Phat Thi Hong","family":"Ho","sequence":"first","affiliation":[{"name":"Department of Pathology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0134-9775","authenticated-orcid":false,"given":"Duy Duc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pathology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuong Dinh Thy","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Oncology Center\u2014Cho Ray Hospital  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giang Huong","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pathology University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"},{"name":"Department of Histology, Embryology and Pathology, School of Medicine University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lam Viet","family":"Trung","sequence":"additional","affiliation":[{"name":"Digestive Surgery Department Cho Ray Hospital  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thinh","family":"Van Hoang","sequence":"additional","affiliation":[{"name":"Department of Pathology Cho Ray Hospital  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang Bac","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, School of Medicine University of Medicine and Pharmacy at Ho Chi Minh City  Ho Chi Minh City Vietnam"},{"name":"University Medical Center Ho Chi Minh City  Ho Chi Minh City Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"issue":"2","key":"e_1_2_13_2_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global Burden of Colorectal Cancer in 2020 and 2040: Incidence and Mortality Estimates From GLOBOCAN","volume":"72","author":"Morgan E.","year":"2023","journal-title":"Gut"},{"issue":"7","key":"e_1_2_13_3_1","first-page":"S118","article-title":"Cost\u2010Effectiveness of New and Emerging Treatment Options for the Treatment of Metastatic Colorectal Cancer","volume":"24","author":"Zadlo J.","year":"2018","journal-title":"American Journal of Managed Care"},{"issue":"36","key":"e_1_2_13_4_1","doi-asserted-by":"crossref","first-page":"38658","DOI":"10.18632\/oncotarget.6130","article-title":"Pattern of Distant Metastases in Colorectal Cancer: A SEER Based Study","volume":"6","author":"Qiu M.","year":"2015","journal-title":"Oncotarget"},{"key":"e_1_2_13_5_1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-8-120","article-title":"Importance of Response to Neoadjuvant Chemotherapy in Potentially Curable Colorectal Cancer Liver Metastases","volume":"8","author":"Gruenberger B.","year":"2008","journal-title":"BMC Cancer"},{"issue":"10","key":"e_1_2_13_6_1","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2007.13.7471","article-title":"Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?","volume":"26","author":"Adam R.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"21","key":"e_1_2_13_7_1","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.7150\/jca.47911","article-title":"The Characteristics and Long\u2010Term Survival of Patients With Colorectal Liver Metastases With Pathological Complete Response After Chemotherapy","volume":"11","author":"Xu D.","year":"2020","journal-title":"Journal of Cancer"},{"issue":"33","key":"e_1_2_13_8_1","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1200\/JCO.2008.17.5299","article-title":"Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases","volume":"26","author":"Blazer D. G.","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"e_1_2_13_9_1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1477-2574.2010.00170.x","article-title":"Pathological Response Grade of Colorectal Liver Metastases Treated With Neoadjuvant Chemotherapy","volume":"12","author":"Chan G.","year":"2010","journal-title":"HPB"},{"issue":"3","key":"e_1_2_13_10_1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1245\/s10434-014-4042-6","article-title":"RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated With Chemotherapy Before Resection of Colorectal Liver Metastases","volume":"22","author":"Zimmitti G.","year":"2015","journal-title":"Annals of Surgical Oncology"},{"issue":"17","key":"e_1_2_13_11_1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174067","article-title":"BRAF Mutations in Colorectal Liver Metastases: Prognostic Implications and Potential Therapeutic Strategies","volume":"14","author":"Wang P. P.","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"e_1_2_13_12_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 Pathways: Mechanisms, Structures and Advances in Therapy","volume":"8","author":"Wang H.","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"e_1_2_13_13_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3748\/wjg.v21.i1.84","article-title":"P53 Mutations in Colorectal Cancer\u2014Molecular Pathogenesis and Pharmacological Reactivation","volume":"21","author":"Li X. L.","year":"2015","journal-title":"World Journal of Gastroenterology"},{"issue":"6","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1158\/1078-0432.CCR-03-0362","article-title":"Characterization of p53 Wild\u2010Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5\u2010Fluorouracil, Oxaliplatin, and Irinotecan","volume":"10","author":"Boyer J.","year":"2004","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"e_1_2_13_15_1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1186\/s12885-022-10039-y","article-title":"Clinical Significance of p53 Protein Expression and TP53 Variation Status in Colorectal Cancer","volume":"22","author":"Kim K. M.","year":"2022","journal-title":"BMC Cancer"},{"issue":"6","key":"e_1_2_13_16_1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1093\/carcin\/bgm012","article-title":"Mutations in TP53 Are a Prognostic Factor in Colorectal Hepatic Metastases Undergoing Surgical Resection","volume":"28","author":"Mollev\u00ed D. G.","year":"2007","journal-title":"Carcinogenesis"},{"issue":"4","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cjp2.53","article-title":"Optimized p53 Immunohistochemistry Is an Accurate Predictor of TP53 Mutation in Ovarian Carcinoma","volume":"2","author":"K\u00f6bel M.","year":"2016","journal-title":"Journal of Pathology Clinical Research"},{"issue":"1","key":"e_1_2_13_18_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-018-0715-8","article-title":"Immunohistochemical Investigation of Prognostic Biomarkers in Resected Colorectal Liver Metastases: A Systematic Review and Meta\u2010Analysis","volume":"18","author":"Tor\u00e9n W.","year":"2018","journal-title":"Cancer Cell International"},{"issue":"15","key":"e_1_2_13_19_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3582","article-title":"The Prognostic Impact of RAS and TP53 Mutation According to Primary Tumor Location in Colorectal Liver Metastases","volume":"39","author":"Cha Y.","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1200\/JCO.1996.14.10.2696","article-title":"p53 Nuclear Protein Overexpression in Colorectal Cancer: A Dominant Predictor of Survival in Patients With Advanced Hepatic Metastases","volume":"14","author":"Belluco C.","year":"1996","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"e_1_2_13_21_1","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0959-8049(97)10165-4","article-title":"Nuclear p53 Protein Expression in Resected Hepatic Metastases From Colorectal Cancer: An Independent Prognostic Factor of Survival","volume":"34","author":"Nitti D.","year":"1998","journal-title":"European Journal of Cancer"},{"issue":"11","key":"e_1_2_13_22_1","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1158\/1078-0432.CCR-04-2389","article-title":"P53 Mutation Analysis of Colorectal Liver Metastases: Relation to Actual Survival, Angiogenic Status, and p53 Overexpression","volume":"11","author":"Jong K. P.","year":"2005","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"5","key":"e_1_2_13_23_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejso.2015.02.003","article-title":"Assessing the TP53 Marker Type in Patients Treated With or Without Neoadjuvant Chemotherapy for Resectable Colorectal Liver Metastases: A p53 Research Group Study","volume":"41","author":"Pilat N.","year":"2015","journal-title":"European Journal of Surgical Oncology (EJSO)"},{"issue":"38","key":"e_1_2_13_24_1","doi-asserted-by":"crossref","first-page":"61107","DOI":"10.18632\/oncotarget.11243","article-title":"Interleukin\u20106 Increases Matrix Metalloproteinase\u201014 (MMP\u201014) Levels via Down\u2010Regulation of p53 to Drive Cancer Progression","volume":"7","author":"Cathcart J. M.","year":"2016","journal-title":"Oncotarget"},{"issue":"18","key":"e_1_2_13_25_1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.4161\/cbt.8.18.9207","article-title":"A Role for p53 in the Regulation of Extracellular Matrix Metalloproteinase Inducer in Human Cancer Cells","volume":"8","author":"Zhu H.","year":"2009","journal-title":"Cancer Biology and Therapy"},{"issue":"27","key":"e_1_2_13_26_1","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1038\/onc.2012.334","article-title":"Mutant p53 Gain\u2010Of\u2010Function Induces Epithelial\u2013Mesenchymal Transition Through Modulation of the miR\u2010130b\u2013ZEB1 Axis","volume":"32","author":"Dong P.","year":"2013","journal-title":"Oncogene"},{"key":"e_1_2_13_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1148389","article-title":"The Role of p53 in Anti\u2010Tumor Immunity and Response to Immunotherapy","volume":"10","author":"Carlsen L.","year":"2023","journal-title":"Frontiers in Molecular Biosciences"},{"issue":"1","key":"e_1_2_13_28_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1101\/gad.14.1.34","article-title":"Regulation of Tumor Angiogenesis by p53\u2010Induced Degradation of Hypoxia\u2010Inducible Factor 1alpha","volume":"14","author":"Ravi R.","year":"2000","journal-title":"Genes and Development"},{"issue":"11","key":"e_1_2_13_29_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in Cancer: From Molecular Mechanism to Therapeutic Modulation","volume":"13","author":"Chen X.","year":"2022","journal-title":"Cell Death and Disease"},{"issue":"24","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1080\/15384101.2019.1688951","article-title":"Mutant p53 Drives Cancer Chemotherapy Resistance due to Loss of Function on Activating Transcription of PUMA","volume":"18","author":"Huang Y.","year":"2019","journal-title":"Cell Cycle"},{"issue":"5","key":"e_1_2_13_31_1","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1078-0432.CCR-19-2390","article-title":"Coaltered Ras\/B\u2010Raf and TP53 Is Associated With Extremes of Survivorship and Distinct Patterns of Metastasis in Patients With Metastatic Colorectal Cancer","volume":"26","author":"Datta J.","year":"2020","journal-title":"Clinical Cancer Research: An Official Journal of the American Association for Cancer Research"},{"issue":"4","key":"e_1_2_13_32_1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/1878-0261.12885","article-title":"Genomic and Prognostic Heterogeneity Among RAS\/BRAF(V600E) \/TP53 Co\u2010Mutated Resectable Colorectal Liver Metastases","volume":"15","author":"Berg K. C. G.","year":"2021","journal-title":"Molecular Oncology"},{"issue":"2","key":"e_1_2_13_33_1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00428-024-03790-z","article-title":"The Pattern\u2010Based Interpretation of p53 Immunohistochemical Expression as a Surrogate Marker for TP53 Mutations in Colorectal Cancer","volume":"486","author":"Osakabe M.","year":"2025","journal-title":"Virchows Archiv"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70701","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70701","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:24:49Z","timestamp":1791012289000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cnr2.70701"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70701","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2025-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70701"}}